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Abstract
Background. Steroid-resistant nephrotic syndromes (NS)
with focal and segmental glomerulosclerosis (FSGS) can
be differentiated into sporadic and syndromic forms. In
sporadic NS, a circulating FSGS-factor is discussed in the
pathogenesis and is thought to inhibit the synthesis of nitric
oxide (NO) from L-arginine by blocking the NO synthase
(NOS). Asymmetric dimethylarginine (ADMA) is an en-
dogenous inhibitor of all types of NOS. In a previous study
we did not find an elevation of ADMA in a syndromic form
of FSGS, the Schimke-immuno-osseous dysplasia. Here we
report for the first time data on the L-arginine/NO pathway
in sporadic FSGS of childhood.
Methods. Nine children (5 to 18 years of age) suffer-
ing from sporadic FSGS and age-matched healthy con-
trols were investigated. ADMA in plasma and urine
as well as L-arginine in plasma were determined by
gas chromatography–tandem mass spectrometry. The NO
metabolites nitrate and nitrite were measured in plasma
and urine by gas chromatography–mass spectrometry (GC-
MS). The ADMA metabolite dimethylamine (DMA) was
measured in urine by GC-MS.
Results.We found elevated plasma levels of ADMA in chil-
dren suffering from sporadic FSGS compared to healthy
controls (851 nmol/L versus 684 nmol/L, P = 0.008). An
inverse correlation between ADMA and glomerular filtra-
tion rate (GFR) was found in sporadic FSGS (Pearson’s
correlation coefficient −0.784, P = 0.012).
Conclusion. Our study suggests that ADMA synthesis is
elevated in sporadic FSGS. This finding argues for the
involvement of ADMA in the pathogenesis of this disease
in childhood.
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Introduction
Focal and segmental glomerulosclerosis (FSGS) repre-
sent a histological variant of nephrotic syndromes (NS) in
childhood [1]. There exist sporadic and syndromic forms
of FSGS. Syndromic forms like the Schimke-immuno-
osseous dysplasia (SIOD) are a subvariant of genetic forms
of FSGS, usually showing no recurrence of FSGS in
transplanted kidneys [2].
In sporadic forms of FSGS, the disease recurs in 30–40%
of transplanted patients [1]. In contrast to syndromic forms
of FSGS, an intrinsic renal disease is unlikely to be the
pathogenetic cause in sporadic FSGS. There is evidence
for a circulating factor playing a role in the pathogenesis
and recurrence of FSGS, by modifying the glomerular
permeability to albumin [3]. It has been speculated that this
so-called FSGS-factor inhibits the synthesis of nitric oxide
(NO) from L-arginine by blocking NO synthase (NOS),
thereby antagonizing the antifibrotic effect of NO within
the mesangium resulting in progressive glomerulosclerosis
[4].
The NOS are a family of enzymes that convert L-arginine
to L-citrulline and NO. The activity of NOS is effec-
tively controlled by the endogenous inhibitor asymmetric
dimethylarginine (ADMA) [5]. ADMA is produced by
methylation of protein-associated L-arginine via N-methyl
protein transferases and subsequent regular proteolysis [6].
NO is a gaseous, freely diffusible molecule with
multiple physiological functions including vasodilation,
inhibition of platelet aggregation and adhesion [7]. NO is
involved in the regulation of regional blood flow and sys-
temic blood pressure. Inhibition of NOS byADMA induces
vascular dysfunction in man [8]. Additionally, suggesting a
causal relationship between NO-mediated vasodilation and
atherosclerosis, studies in the cholesterol-fed rabbit model
for atherosclerosis showed that administration of L-arginine
prevented the loss of endothelial-dependent vasodilation
[9]. In that study, hypercholesterolaemic rabbits were found
to have elevated plasma concentrations of ADMA [9].
C© The Author [2008]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.
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Table 1. Parameters of L-arginine/NO pathway in healthy controls, patients with FSGS and non-FSGS renal diseases
Aged-matched healthy controls FSGS Non-FSGS renal diseases
ADMA plasma (nmol/L) mean (SD) 683 (106) 851 (108)∗ 788 (130)
Arginine plasma (µmol/L) mean (SD) 77 (29) 56 (14) 60 (11)
Nitrate plasma (µmo/L) mean (SD) 91 (73) n = 7 71 (24) 115 (60)
Nitrite plasma (µmol/L) mean (SD) 3.2 (1.1) n = 7 2 (1.1) 3 (1.5)
ADMA urine (µmol/mmol creatinine) mean (SD) 15.7 (26) 41 (55) 5.7 (6)
DMA urine (µmol/mmol creatinine) mean (SD) 160 (248) 345 (489) 130 (155)
Nitrate urine (µmol/mmol creatinine) mean (SD) 421 (712) 262 (419) 174 (204)
Nitrite urine (µmol/mmol creatinine) mean (SD) 1.3 (2) 3.0 (5) 1.3 (1.5)
Age (years) mean (SD) 11 (4.6) 11 (4.2) 4 (2.8)
Number of children 9 9 11
GFR (ml/min/1.73 m2bs) mean (SD) nd 72 (55) 32 (44) n = 9
Hypertension no n = 5 n = 5
Cholesterol (mg/dL) nd 269 212
Serum protein (g/L) nd 65 (11) 60 (20)
Protein/creatinine in urine (g/mmol) nd 0.3 (0.5) 1.4 (1.9) n = 8
∗P < 0.05 versus controls (GFR = glomerular filtration rate, m2bs = square metre body surface, nd = not determined).
Elevated ADMA levels have been measured in plasma
of adults with decreased renal function [10], but the role
of the kidney in accumulation of ADMA is contradictory.
It is believed that the kidney plays a role in the direct
elimination of ADMA [11]. However, the greatest frac-
tion (∼80%) of ADMA is assumed to be first hydrolysed
by the enzyme dimethylarginine dimethylaminohydrolase
(DDAH) to L-citrulline and dimethylamine (DMA) [6].
DDAH is highly expressed in the liver and in the kidney
[12]. In humans, systemic infusion of ADMA in healthy
adults caused a dose-dependent decrease of renal plasma
flow, with glomerular filtration rate (GFR) remaining un-
changed, a decrease in cardiac output and an increase of
systemic vascular resistance and blood pressure [13]. Since
elevated circulating levels of ADMA have been found in
a variety of diseases, most of them being associated with
NO-dependent endothelial dysfunction [14,15], ADMA is
considered a novel marker for cardiovascular risk in adults
[8,10].
Recently we reported that the L-arginine/NO pathway is
not involved in the pathogenesis of SIOD, a syndromic form
of FSGS [16]. The aim of the present study was to assess
the L-arginine/NO pathway in children with sporadic FSGS
and to investigate a potential role of ADMA in this disease.
Subjects and methods
Nine childrenwith sporadic FSGS and age-matched healthy
controls were investigated. These groups were compared
to 11 children with renal diseases other than FSGS (non-
FSGS) as pathological controls. The characteristics of the
patients included in the present study are summarized in
Table 1 (sporadic FSGS) and Table 2 (non-FSGS). The
patients were not tested for FSGSmutations. The study was
approved by the Ethics Committee of Hannover Medical
School and written informed consent was obtained from
the parents.
The synthesis and elimination of ADMA were as-
sessed by measuring circulating and excretory ADMA
as well as excretory DMA. ADMA in plasma and urine
as well as L-arginine in plasma were determined by gas
chromatography–tandemmass spectrometry (GC-MS-MS)
as described elsewhere [17]. Urinary DMA was measured
by gas chromatography–mass spectrometry (GC-MS) [18].
NO synthesis was assessed by measuring the plasma and
urinary concentrations of nitrite and nitrate, the major NO
metabolites and indicators ofNO synthesis [19]. Nitrate and
nitrite in plasma and urine were determined simultaneously
by GC-MS, as described previously [16,20].
Urinary excretion of all biochemical parameters was
corrected for creatinine excretion. Creatinine concentra-
tion in urine was determined by high-performance liquid
chromatography (HPLC) [16,21].
Sample size varied due to limited urine and blood
volumes available in young children. GFR was calculated
using the Schwartz formula.
Data from patients and healthy controls were compared
using theWilcoxon test (SPSS, version 13). The non-FSGS
groupwas compared with controls or the FSGS group using
the Student’s t-test for unpaired samples. Values of
P< 0.05 were considered significant. Data were presented
as mean ± SD.
Results
Plasma levels of ADMA in nine patients with sporadic
FSGS were significantly higher than in healthy controls
(851 ± 108 versus 683 ± 106 nmol/L, P = 0.008), though
there was some overlap (Figure 1A). In the sporadic FSGS
group, children with hypertension had insignificantly (P =
0.13) higher ADMA plasma levels as compared to nor-
motensive children (896 ± 48 versus 788 ± 130 nmol/L).
Plasma levels of ADMA were higher in the group of
children with sporadic FSGS than in children with renal
diseases other than FSGS (non-FSGS); however, this
difference was not statistically significant (P = 0.44). Fur-
thermore, the elevation of ADMA plasma levels in the
non-FSGS group was not statistically different compared
to healthy controls (P = 0.26). In addition, within the non-
FSGS group, patients without dialysis or transplantation did
not show differences in plasma ADMA levels compared to
patients with dialysis or transplantation.
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Fig. 1. Plasma concentrations of ADMA (A), nitrate (B) and nitrite (C)
in healthy controls (n = 9) and patients with sporadic FSGS (total: n = 9;
Tx: n= 1; HD: n= 1) and non-FSGS (total: n= 11; Tx: n= 1; HD: n= 6).
Data from patients under dialysis and after transplantation are indicated
by rhombus and triangle, respectively. sp. FSGS = sporadic FSGS.
Renal excretion of ADMA was slightly but not signifi-
cantly higher in patients with sporadic FSGS (41.4 ± 55
versus 15.7 ± 26 µmol/mmol creatinine, P = 0.314) com-
pared to healthy controls (Figure 2A; Table 3). Compared
to healthy controls, creatinine-corrected excretion of DMA
in urine was tendentiously higher in patients with sporadic
FSGS (345 ± 489 versus 160 ± 248 µmol/mmol creati-
nine, P = 0.06; see Figure 2B; Table 1). DMA excretion
rate in the non-FSGS group was not statistically different
compared to healthy controls (P = 0.73).
In plasma, nitrate (91.4 ± 73 versus 71.3 ± 24 µmol/L,
P = 0.779; Figure 1B) and nitrite (2.0 ± 1.1 versus 3.2 ±
1.1 µmol/L, P = 0.093) (Figure 1C) of the FSGS group
were not significantly different from healthy controls.
Creatinine-corrected excretion of nitrate (262± 419 versus
421 ± 712 µmol/mmol creatinine, P = 0.314; Figure 2C)
and nitrite (3.0± 5.0 versus 1.3± 2µmol/mmol creatinine,
P = 0.2; Figure 2D) of the FSGS group did not differ
statistically from healthy controls. L-Arginine plasma levels
were not statistically different between the groups (P =
0.11, Table 3).
Fig. 2. Creatinine-corrected excretion rates of ADMA (A), DMA (B),
nitrate (C) and nitrite (D) in healthy controls (n = 9) and patients with
sporadic FSGS (total: n = 9; Tx: n = 1; HD: n = 1) and non-FSGS (total:
n = 11; Tx: n = 1; HD: n = 6). Data from patients under dialysis and
after transplantation are indicated by rhombus and triangle, respectively.
sp. FSGS = sporadic FSGS.
An inverse correlation (Pearson’s correlation coefficient
(r) −0.784, P = 0.012) was found between ADMA in
plasma and GFR in non-HD (haemodialysis) sporadic
FSGS patients (Figure 3), but not in non-FSGS children
(not shown). No statistically significant differences were
found between the GFR of the FSGS and the GFR of the
non-FSGS group (P= 0.8; HD patients were excluded). No
correlation was found between urinary DMA and ADMA
(r = 0.625, P = 0.097) or between urinary DMA and GFR
(r = −0.2, P = 0.64) in the sporadic FSGS group.
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Fig. 3. Correlation between plasma ADMA concentration and GFR in
sporadic FSGS (non-HD) patients. Pearson’s correlation coefficient r =
−0.784, P = 0.012. sp. FSGS = sporadic FSGS.
The sporadic FSGS group consisted of five children with
hypertension and four normotensive patients. GFR val-
ues did not differ statistically in these subgroups. In both
groups, a trend of negative correlation was found between
ADMA plasma levels and GFR.
Discussion
NS is associated with an increased risk for cardiovas-
cular disorders; thromboembolic complications and pre-
mature atherosclerosis are typical findings in adults and
even in children [1]. However, data on the status of the
L-arginine/NO pathway in nephrotic children are rare.
Recently, we showed that this pathway does not play a role
in the pathogenesis of SIOD, a syndromic form of FSGS
[16]. Importantly, plasma levels of ADMA in 10 SIOD
patients (691 ± 168 nmol/L) were not significantly differ-
ent (P = 0.78) from those in age-matched controls (677 ±
138 nmol/L) [16].
To our knowledge, the present study is the first to inves-
tigate the L-arginine/NO pathway in children with sporadic
FSGS. We found that these children had elevated levels
of ADMA in plasma compared to healthy controls. In our
study, GFR of the sporadic FSGS group and the non-FSGS
group did not show significant differences, while only in the
sporadic FSGS group was ADMA in plasma significantly
elevated compared to healthy controls. Thus, impairment
of renal function does not explain our finding of elevated
ADMA levels in plasma of children with sporadic FSGS.
Urinary excretion rates of ADMA and DMA in patients
with sporadic FSGS were even higher than those of healthy
controls, also suggesting that the elevation of ADMA lev-
els in the circulation did not result from an impaired renal
elimination of ADMA or a reduced activity of DDAH in
sporadic FSGS.
Cholesterol levels were slightly higher in the group of pa-
tientswith sporadic FSGS compared to the group of patients
with non-FSGS (Table 3), which was to be expected if the
non-FSGS renal diseases were not nephritic. However, we
do not think that the slight elevation of cholesterol can ex-
plain the elevated ADMA in plasma of children with FSGS,
because even in children with hypercholesterolaemia type
IIa, circulating ADMA levels did not differ significantly
compared to age-matched healthy controls [22].
The L-arginine/NO pathway may influence the differ-
entiation and mobilization of endothelial progenitor cells
(EPcC) [23], which replace damaged endothelial cells in
vaso-occlusive vessels [24]. EPC were found to be reduced
in vaso-occlusive diseases, as in coronary artery disease
[25]. ADMA has been shown to suppress EPC in coronary
artery disease [26]. Taking into account that sporadic FSGS
can be regarded as a renal vaso-occlusive disease, elevated
ADMA levels might decrease EPC in this disease, thereby
causing a progression of renal vascular lesions and decreas-
ing the GFR. The findings of the present study, of elevated
plasma concentration of ADMA in sporadic FSGS, and the
inverse relationship between ADMA in plasma and GFR in
patients with sporadic FSGS, but not in children with other
renal diseases, are supportive of this hypothesis.
A negative relationship between ADMA plasma concen-
tration andGFRhas been reported for hypertensive children
and adolescents [27]. The subgroups of hypertensive and
normotensive patients of the sporadic FSGS group of the
present study are rather small and do not allow reliable com-
parison. Nevertheless, our findings suggest that the inverse
correlation of circulating ADMA levels and GFR found in
the sporadic FSGS group of our study is likely to be asso-
ciated with the renal disease rather than with hypertension.
In healthy adults, short-term infusion of ADMA has been
shown not to affect GFR at all [13]. Presumably, this
apparent discrepancy may be explained by the duration of
action of ADMA, which is rather chronic in sporadic FSGS
patients.
Since patients with sporadic FSGS show a high per-
centage of recurrence of the disease after transplantation,
ADMA concentrations in plasma may serve as a follow-up
parameter for the severity of sporadic FSGS or recurrence
of the disease after renal transplantation. However, due to
small sample size, subgroup analysis is limited in our study.
Ongoing studies of our group focus on the influence of
dialysis and kidney transplantation on ADMA synthesis
and elimination in childhood.
Recently, we presented an anthropometric instrument
to distinguish SIOD, a syndromic form of FSGS, from
non-SIOD renal diseases [28]. ADMA levels in plasma
of patients with this syndromic form of FSGS were normal
[16]. Since, we have now found elevated plasma levels of
ADMA in children with sporadic FSGS, the measurement
of ADMA in plasma in combination with anthropomet-
ric parameters may be an appropriate tool to distinguish
syndromic from sporadic forms of FSGS. However, further
studies are necessary to prove this hypothesis.
In summary, elevated ADMA concentrations in plasma
of children suffering from sporadic FSGS, presumably
resulting from enhancedADMA synthesis, suggest a role of
ADMA in the pathophysiology of this nephrotic syndrome.
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